Investment
Features
FeesSafety
Academy
More
Pluang+

Compare INNIO N.V. Ordinary Shares (INIO) vs Iovance Biotherapeutics Inc. Common Stock (IOVA) Price & Performance

INNIO N.V. Ordinary SharesTrade
Iovance Biotherapeutics Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

INNIO N.V. Ordinary Shares vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? INNIO N.V. Ordinary Shares trades at $16 (market cap $13.73B), while Iovance Biotherapeutics Inc. Common Stock trades at $14.13 (market cap $6.57B). The key difference: INNIO N.V. Ordinary Shares is far larger — about 2.1× Iovance Biotherapeutics Inc. Common Stock's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, INNIO N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold INNIO N.V. Ordinary Shares for 0 Days and Iovance Biotherapeutics Inc. Common Stock for 1 Days on average.

INIOIOVA
Market Cap
$13.73B$6.57B
Volume
5,012,19511,838,721
Sector
IndustrialsHealth
52-Week High
$41.13$14.82
52-Week Low
$16.50$1.81
Typical Hold Time
0 Days1 Days
Enterprise Value
$15.39B$6.50B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

INNIO N.V. Ordinary Shares

No Aura AI signal available yet.

Iovance Biotherapeutics Inc. Common Stock

Iovance Biotherapeutics (IOVA) trades at $14.50, down 0.41% on the day, with a bullish technical signal from moving averages. The company shows strong revenue growth, with 2026 guidance raised to $410–420 million, but remains unprofitable with a net income margin of -89.09%. Recent news highlights institutional buying and positive analyst sentiment driven by accelerating adoption of its Amtagvi therapy.

The outlook is optimistic due to expanding TIL therapy applications and raised revenue guidance, but high cash burn and lack of profitability pose significant risks. Analyst consensus is strongly bullish with a $13.44 price target, though the stock faces volatility from clinical trial outcomes and competitive pressures.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

INIO
100% Buy0% Sell
Avg holding period · 0 Days
IOVA
100% Buy0% Sell
Avg holding period · 1 Days

About INNIO N.V. Ordinary Shares

INNIO Group designs, manufactures, and services reciprocating gas engines for distributed power generation under its Jenbacher and Waukesha brands, serving applications from data centers to industrial and grid-stabilization uses.

Read more on INIO →

About Iovance Biotherapeutics Inc. Common Stock

Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.

Read more on IOVA →